Your browser doesn't support javascript.
loading
Obesity and triple-negative-breast-cancer: Is apelin a new key target?
Gourgue, Florian; Mignion, Lionel; Van Hul, Matthias; Dehaen, Natacha; Bastien, Estelle; Payen, Valery; Leroy, Baptiste; Joudiou, Nicolas; Vertommen, Didier; Bouzin, Caroline; Delzenne, Nathalie; Gallez, Bernard; Feron, Olivier; Jordan, Bénédicte F; Cani, Patrice D.
Afiliación
  • Gourgue F; Metabolism & Nutrition Research Group, Louvain Drug Research Institute, WELBIO (Walloon Excellence in Life sciences and BIOtechnology), UCLouvain, Université catholique de Louvain, Brussels, Belgium.
  • Mignion L; Biomedical Magnetic Resonance Research Group, UCLouvain, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium.
  • Van Hul M; Biomedical Magnetic Resonance Research Group, UCLouvain, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium.
  • Dehaen N; Metabolism & Nutrition Research Group, Louvain Drug Research Institute, WELBIO (Walloon Excellence in Life sciences and BIOtechnology), UCLouvain, Université catholique de Louvain, Brussels, Belgium.
  • Bastien E; Biomedical Magnetic Resonance Research Group, UCLouvain, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium.
  • Payen V; Pole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique, UCLouvain, Université catholique de Louvain, Brussels, Belgium.
  • Leroy B; Pole of Pediatrics, Institut de Recherche Expérimentale et Clinique, UCLouvain, Université catholique de Louvain, Brussels, Belgium.
  • Joudiou N; Laboratory of Proteomics and Microbiology, MS-Quanta Platform, Research Institute for Biosciences, University of Mons, Mons, Belgium.
  • Vertommen D; Nuclear and Electron Spin Technologies (NEST) Platform, Louvain Drug Research Institute (LDRI), UCLouvain, Université catholique de Louvain, Brussels, Belgium.
  • Bouzin C; de Duve Institute (DDUV), Université catholique de Louvain (UCLouvain), Brussels, Belgium.
  • Delzenne N; Imaging platform 2IP, Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Université catholique de Louvain, Brussels, Belgium.
  • Gallez B; Metabolism & Nutrition Research Group, Louvain Drug Research Institute, WELBIO (Walloon Excellence in Life sciences and BIOtechnology), UCLouvain, Université catholique de Louvain, Brussels, Belgium.
  • Feron O; Biomedical Magnetic Resonance Research Group, UCLouvain, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium.
  • Jordan BF; Pole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique, UCLouvain, Université catholique de Louvain, Brussels, Belgium.
  • Cani PD; Biomedical Magnetic Resonance Research Group, UCLouvain, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium.
J Cell Mol Med ; 24(17): 10233-10244, 2020 09.
Article en En | MEDLINE | ID: mdl-32681609
ABSTRACT
Epidemiological studies have shown that obese subjects have an increased risk of developing triple-negative breast cancer (TNBC) and an overall reduced survival. However, the relation between obesity and TNBC remains difficult to understand. We hypothesize that apelin, an adipokine whose levels are increased in obesity, could be a major factor contributing to both tumour growth and metastatization in TNBC obese patients. We observed that development of obesity under high-fat diet in TNBC tumour-bearing mice significantly increased tumour growth. By showing no effect of high-fat diet in obesity-resistant mice, we demonstrated the necessity to develop obesity-related disorders to increase tumour growth. Apelin mRNA expression was also increased in the subcutaneous adipose tissue and tumours of obese mice. We further highlighted that the reproduction of obesity-related levels of apelin in lean mice led to an increased TNBC growth and brain metastases formation. Finally, injections of the apelinergic antagonist F13A to obese mice significantly reduced TNBC growth, suggesting that apelinergic system interference could be an interesting therapeutic strategy in the context of obesity and TNBC.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama Triple Negativas / Apelina / Obesidad Límite: Animals Idioma: En Revista: J Cell Mol Med Asunto de la revista: BIOLOGIA MOLECULAR Año: 2020 Tipo del documento: Article País de afiliación: Bélgica

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama Triple Negativas / Apelina / Obesidad Límite: Animals Idioma: En Revista: J Cell Mol Med Asunto de la revista: BIOLOGIA MOLECULAR Año: 2020 Tipo del documento: Article País de afiliación: Bélgica